Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer, with low survival rates and 30 limited therapeutic options. Thus, the elucidation of signaling pathways involved in PDAC pathogenesis 31 is essential to identify novel potential therapeutic gene targets. Here, we used a systems approach by 32 integrating gene and microRNA profiling analyses together with CRISPR/Cas9 technology, to identify 33 novel transcription factors involved in PDAC pathogenesis. FOXA2 transcription factor was found to be 34 significantly down-regulated in PDAC relative to control pancreatic tissues. Functional experiments 35 revealed that FOXA2 has a tumor suppressor function through inhibition of pancreatic cancer 36 cell growth, migration, invasion and colony formation. In situ hybridization analysis revealed 37 miR-199a significantly upregulated in pancreatic cancer. Bioinformatics and luciferase analyses 38 showed that miR-199a negatively regulates directly FOXA2 expression, through binding in its 3' 39 untranslated region (UTR). Evaluation of the functional importance of miR-199 on pancreatic 40 cancer revealed that miR-199 acts as an inhibitor of FOXA2 expression, inducing an increase in 41 pancreatic cancer cell proliferation, migration and invasion. Additionally, gene ontology and 42 network analyses in PANC-1 cells treated with an siRNA against FOXA2 revealed an 43 enrichment for cell invasion mechanisms through PLAUR and ERK activation. FOXA2 deletion 44 (FOXA2Δ) by using two CRISPR/Cas9 vectors in PANC-1 cells, induced tumor growth in vivo, 45 resulting in up-regulation of PLAUR and ERK pathways in FOXA2Δ xenograft tumors. Taken 46 together, we have identified FOXA2 as a novel tumor suppressor in pancreatic cancer, regulated 47 directly by miR-199a, enhancing our understanding on how microRNAs interplay with the 48 transcription factors to affect pancreatic oncogenesis. 49 50 51 Keywords: FOXA2, miR-199a, CRISPR/Cas9, pancreatic cancer 52 53 54
Pancreatic ductal adenocarcinoma (PDAC) accounts for >85% of all the pancreatic cancer cases. 57 For all stages combined, the 1-and 5-year relative survival rates are 28% and 7%, respectively. FBS, horse serum to a final concentration of 2.5% and 10 units/ml penicillin and 100 μg/ml 137 streptomycin. Transcription factor expression analysis 149 To identify transcription factors that were differentially expressed in pancreatic ductal 150 adenocarcinoma, microarray was performed using GeneChip® Human Genome U133 Plus 2.0 151 Arrays. RNA was isolated from 14 PDAC and 8 control tissues. In the list of top differentially 152 expressed genes, FOXA2 was found to be down-regulated in PDAC (cut off was 2-fold change, 153 p<0.05).
155
Invasion Assays 156 We performed invasion assays in PANC-1 and HPAF-II cells at 24 hours under different Migration Assays 167 PANC-1 and BxPC-3 pancreatic cancer cell lines were used in this assay. The migration assay 168 was performed by starving cells overnight in media containing 0% FBS. The next day, cells were 169 re-suspended in media with 0.5% FBS to a concentration of 5×10 5 /ml. The upper chamber was 170 loaded with 100 μL of cell suspension and the lower chamber was loaded with 500 μL medium 171 containing 20% FBS as a chemoattractant. The cells on the bottom of each chamber were fixed 172 with 0.1% glutaraldehyde for 30 min, rinsed briefly with PBS and stained with 0.2% crystal 173 violet. The number of migrated cells was calculated using 20X magnification and the mean for 174 each chamber was determined. The results were calculated as the migration rate as compared 175 with the siRNA negative control (or miRNA-NC) cells. Each experimental condition was 176 conducted in triplicates and the experiment was repeated three times.
178
Colony Formation Assays 179 PANC-1 cells were transfected with siRNA negative control or siFOXA2#2 for 48 hours. 180 Triplicate samples of 10 5 cells from each cell line were mixed 4:1 (v/v) with 2.0% agarose in 181 growth medium for a final concentration of 0.4% agarose. The cell mixture was plated on top of 182 a solidified layer of 0.8% agarose in growth medium. Cells were fed every six to seven days with 183 growth medium containing 0.4% agarose. The number of colonies was counted after 20 days. 184 The experiment was repeated three times and the statistical significance was calculated using the 185 Student's t-test. In situ hybridization 189 Double-DIG labeled Mircury LNA probes were used for the detection of hsa-miR-199a-3p 190 (38481-15, Exiqon) with target sequence ACAGUAGUCUGCACAUUGGUUA. In situ 191 hybridization protocol was used as previously described (Iliopoulos et al., 2009b) was assessed using the Cell-Titer Glo Luminescence Cell Viability Assay (G7571, Promega).
279
The xCELLigence RTCA SP system utilizes a 96-well microtiter detection device, where the 280 microelectrode sensor arrays are coated in 96-well microtiter plates and the microtiter plate 281 detection device is connected to the workstation from the inside of the cell incubator. The 282 impedance data from the selected well is exported to the computer and analyzed using RTCA were transfected with miR-NC or miR-199. 24 hours post-transfection, cells were trypsinized 287 and cells were re-suspended at 5×10 3 cells/100 μL and 5×10 3 cells were seeded into each well of 288 the E-plate 96 in quadruplicates.
290
Mouse experiments 291 5x10 6 PANC-1 control or PANC-1 FOXA2Δ cells were injected subcutaneously in the right 292 flank of NOD/SCID mice (n= 10 mice/group). Tumor growth was monitored every seven days 293 for a total period of 64 days. Tumor volumes were calculated by the equation V (mm 3 ) = axb 2 /2, 294 where "a" is the largest diameter and b is the perpendicular diameter. In addition, paraffin 295 embedded tissue sections from pancreatic tissues from male 3-month and 9-month old, male, ERK antibody (4695, Cell Signaling), as well as total AKT (4691S, Cell Signaling) and 317 phospho-AKT T308 (13038S, Cell Signaling) and phosphor-AKT S473 (4060S, Cell Signaling).
318
Additionally, CREB and GAPDH antibodies were used as loading controls (9104, Cell Signaling 319 and 5174, Cell Signaling, respectively).
320

Small interfering RNAs
321
The following siRNAs were used in this study: siRNA negative control (siNC #2, 4390847, Life The FOXA2 human gene knockout kit via CRISPR was ordered from OriGene (KN204066).
342
Clones were selected using 2μg/ml puromycin. Where N is the number of genes in the network of which G are central node genes, for a pathway 364 of s genes of which f are central node genes. C(n,k) is the binomial coefficient. We considered 365 statistically significant networks those with a score greater than 5 (p value <10 −5 ). (Figure 2A) . 409 Although siRNA#2 had a higher knockdown efficiency than siRNA#1 against FOXA2 (data not 410 shown), when cells were transfected with either siRNA#1 or siRNA#2, a statistically significant 411 increase in cell growth was observed in both PANC-1 and BxPC-3 cell lines, 48 hours post 412 transfection (Figure 2A) . Due to the higher knockdown efficiency, siRNA#2 was used in the properties, we performed cell migration and invasion assays in PANC-1 (Figure 2C and D) and 417 BxPC-3 cells (Figure 2E and F) . A statistically significant higher number of migrating and MiR-199a negatively regulates FOXA2 expression through binding in its 3'UTR. 427 We were interested in identifying the molecular mechanism involved in the suppression of (Figure 3A) . To examine the direct interaction between miR-199a and FOXA2, we (Figure 3B) . To further validate the interaction 442 between miR-199a and FOXA2 in vitro, miR-199 was overexpressed in PANC-1 cells. We 443 examined FOXA2 mRNA and protein levels, and found that FOXA2 levels significantly 444 decreased in miR-199a-overexpressing pancreatic cancer cells (Figure 3C, D) . Taken together, 445 these findings suggest that miR-199a is a direct regulator of FOXA2 expression in pancreatic 446 cancer.
448
MiR-199a has an oncogenic function in PDAC. 449 Next, we were interested in investigating the relevance of miR-199a in human pancreatic cancer. (Figure 4B) . To explore the functional role of miR-199 in 457 pancreatic oncogenesis we used the xCELLigence technology to monitor cell growth over a 458 period of 120 hours, with a measurement taken every 15 minutes. This assay showed that miR-459 199a significantly increases the growth of PANC-1 cells (Figure 4C) . Cell growth was also 460 performed with the same experimental samples using the CellTiter-Glo Luminescent Cell 461 Viability assay. MiR-199a overexpression led to a 50% increase in PANC-1 cell growth 462 compared to cells transfected with a microRNA negative control (Figure 4C) . To further assess 463 the functional effects of miR-199a overexpression in pancreatic cancer, we performed migration 464 and invasion assays in PANC-1 cells and found a statistically higher number of migrating and 465 invading cells in the miR-199a-overexpressing PANC-1 cells relative to cells transfected with 466 the microRNA negative control (Figure 4D and E) . FOXA2-regulated gene network in PDAC. 469 Our data revealed that FOXA2 has tumor suppressor properties in PDAC and its expression is 470 regulated by miR-199a. To evaluate the molecular mechanisms that are regulated by FOXA2 471 suppression in PDAC and identify its downstream gene targets, we transiently knocked down 472 FOXA2 using siFOXA2#2 in PANC-1 cells and its corresponding negative control, 473 demonstrating an 80% inhibition of FOXA2 mRNA expression levels (Figure 5A) . Next, we 474 performed gene profiling analysis and found that 372 genes were up-regulated, while 552 were 475 down-regulated (924 genes in total) in siFOXA2#2 PANC-1 cells relative to siRNA negative 476 control by using a cut-off of p<0.05 and a fold change of 2 ( Figure 5B) . The Ingenuity Pathway 477 Analysis (IPA) software was employed to perform signaling pathway analysis. The results 478 revealed statistically significant enrichment for the cell movement/invasion pathway, cell 479 proliferation, PI3K/AKT and MAPK signaling pathways (Figure 5C) . To further evaluate these 480 findings we performed gene network analysis by using the 924 differentially expressed genes in 481 the IPA software network analysis and found that the most significant (p value =10 -42 ) gene 482 network was involved in cellular invasion having PLAUR, extracellular signal-regulated kinases 483 (ERK), and phosphoinositide 3-kinase (PI3K) as central nodes, consistent with our pathway 484 analysis (Figure 5D) . Consistent with IPA network analysis data, inhibition of FOXA2 in 485 HPAF-II cells leads to activation of ERK, demonstrated by ERK phosphorylation (Figure 5E) , 486 suggesting that FOXA2 suppression directly or indirectly leads to ERK activation. Interestingly,
487
PLAUR is a gene known to be related to cancer cell invasiveness and motility (14, 29, 67) . To Figure 5H) , indicating activation of the NF-kB pathway.
507
Generating a FOXA2Δ pancreatic cell line using the CRISPR/Cas9 system. 508 We observed the effects of FOXA2 inhibition of expression in vitro through a series of 509 functional and gene expression assays. In order to study the effects of FOXA2 deletion in vivo, 510 we developed a cell line with a permanent knock-out of FOXA2 at the chromosomal level 511 (FOXA2Δ). We used the CRISPR/Cas9 system, where we co-transfected PANC-1 cells with two 512 FOXA2 gRNA vectors, containing two different target sequences (Figure 6A ) and the 513 corresponding donor control vector. After clonal selection in puromycin, we validated FOXA2Δ 514 at the protein level ( Figure 6B) and also found a significant increase in PLAUR mRNA levels in 515 FOXA2Δ compared to control (Figure 6C) , consistent with our siRNA experimental setting.
516
Next, we examined the phosphorylation levels of ERK and AKT by western blot and found both 517 kinases to be activated in FOXA2Δ compared to control, consistent with our gene network 518 analysis (Figure 6D and E) . Conclusively, this data demonstrates the high efficiency of the 519 CRISPR/Cas9 system, its consistency with the siRNA system, providing us with a powerful tool 520 to study the role of FOXA2 in vivo. 
523
To further support the role of FOXA2 as a tumor suppressor gene in pancreatic cancer, we 524 wanted to test its properties in vivo. We performed subcutaneous injections in NOD/SCID mice 525 with either FOXA2Δ PANC-1 (5x10 5 cells) or its corresponding PANC-1 control cell line 526 (n=10/group). On day 64, mice were sacrificed and tumors were isolated. The FOXA2Δ tumor 527 volumes (mm 3 ) and weight (g) were significantly larger than the PANC-1 control tumors 528 (Figure 7A, B and C) . On day 64, RNA was isolated from each tumor and quantitative real-529 time PCR showed that FOXA2 was not expressed in the FOXA2Δ tumors relative to controls 530 (Figure 7D) . Furthermore, in accordance with our in vitro findings, FOXA2Δ tumors showed 531 increased PLAUR mRNA levels (Figure 7E) . Moreover, E-cadherin levels decreased in 532 FOXA2Δ tumors, indicating FOXA2 may also regulate cellular motility (Figure 7F) . Taken 533 together, the in vivo data suggest that inhibition of FOXA2 increases the pancreatic 534 tumorigenicity and aggressiveness. Our study revealed FOXA2 as a novel tumor suppressor gene in pancreatic cancer. FOXA2 is a 539 455-amino acid member of the forkhead class of DNA-binding proteins and contains a highly 540 conserved winged-helix DNA-binding domain (56). FOXA2 is a transcription factor that was 541 initially identified in hepatocytes, where it binds in the promoter areas of important liver-542 enriched genes transthyretin, alpha 1-antitrypsin and albumin (13, 19, 28) . It is required for the 543 formation of the node, notochord, nervous system, and endoderm-derived structures (19, 36) . In 544 adulthood, FOXA2 has been shown to control metabolic homeostasis and to contribute to insulin 545 resistance (65). that miRNAs control many cellular processes through involvement in development, proliferation, 572 the stress response, apoptosis, cell cycle progression, and differentiation (3, 5, 6, 16, 47) . The (18, 23, 24, 26, 52, 57) . Our 578 data indicate that miR-199a-3p plays an oncogenic role, with a significant increase in expression 579 in PDAC compared to control. In the last decade, investigations have revealed that the 580 expression of miRNA-199 is altered in several human cancers (22, 42, 70) . Specifically, the 581 expression of miRNA-199 is increased in ovarian cancer cells and cervical carcinomas (22, 70) 582 in accordance to our data in PDAC. Specifically, overexpression of miR-199 in pancreatic cancer 583 cells led to an increase in pancreatic cell growth, migration and invasion in vitro, demonstrating 584 miR-199 oncogenic properties in pancreatic cancer.
586
We found that miR-199a-3p directly regulates FOXA2 mRNA and protein expression, through 587 binding in its 3'UTR. Furthermore, recent studies have identified additional downstream targets 588 of miR-199 in other cancer types. For example, miR-199 targets Frizzled type 7 receptor 589 (FZD7), one of the most important Wnt receptors involved in cancer development and 590 progression (59). Additionally, mTOR, c-MET, IKKβ, MET proto-oncogene and CD44 have 591 also been identified as direct targets of miR-199, playing a major role in cancer initiation and 592 progression in different types of cancer (10, 17, 21, 27, 39) . confound the interpretation of screen results (35) . Recently, the emergence of CRISPR/Cas9 600 technique offers a novel and versatile platform for genetic screen studies (4, 11, 53) . For these 601 reasons, we chose the highly efficient CRISPR/Cas9 deletion system to permanently knock-out 602 FOXA2 in a pancreatic cancer cell line to study its effects in vivo. In addition, inhibition of 603 FOXA2 expression levels by CRISPR/Cas9 in vitro, led to the activation of PLAUR gene, which 604 is known to be involved in cancer invasiveness (38) . Importantly, these findings were consistent 605 with our data where FOXA2 expression was suppressed by siRNA, suggesting that the 606 CRISPR/Cas9 system is very effective to block gene expression in cancer cells. Taken together, 607 our study has revealed a novel signaling pathway, consisting of the miR-199 and FOXA2 tumor 608 suppressor gene involved in pancreatic oncogenesis. 
